NanoViricides

NanoViricides, Inc. is a development stage company, which engages in the development of nanomedicine drugs against viruses. It focuses on anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs. The company was founded by Anil R. Diwan on April 1, 2005 and is headquartered in Shelton, CT.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NanoViricides, Inc. is a clinical stage company, which engages in the development of nanomedicine drugs against viruses. It focuses on anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs. The company was founded by Anil R. Diwan on April 1, 2005 and is headquartered in Shelton, CT.

SHELTON, CT / ACCESSWIRE / March 2, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicine technology platform, reported today on the strong pan-coronavirus effectiveness of its two COVID-19 clinical drug candidates for which the Company is preparing a pre-IND application. NV-CoV-2 is the Company's broad-spectrum anti-coronavirus clinical lead drug candidate for the treatment of COVID-19 patients based on its nanoviricides® platform.

NanoViricides, Inc. Pan-coronavirus Clinical Drug Candidates for the Treatment of COVID-19 Are Highly Effective in Pre-clinical Cell Culture Studies Performed in Preparation of FDA Pre-IND Application

NanoViricides Inc (NYSE: NNVC) has reported data from animal studies evaluating its broad-spectrum antiviral drug candidate NV-CoV-2 to treat COVID-19 infections.  The treatment candidate was well tolerated in safety pharmacology studies in both rat and non-human primate models.

NanoViricides' Broad-Spectrum Antiviral Drug Candidate Shows Encouraging Action In Preclinical Studies For COVID-19

New York, New York--(Newsfile Corp. - November 18, 2020) - NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, was the subject of a recent article on leading financial news website and publisher, Small Caps Daily. NanoViricides' progress and advancement to clinical trials, developing a therapy to combat COVID-19 and an exploration of the technology behind NV-CoV-1, which is NanoViricides'...

Small Caps Daily Features NanoViricides' Rapid Advancement to Clinical Trials for its COVID-19 Therapy

As the confirmed Covid-19 death toll nears the 1.3 million mark, pharma and biotech companies all over the world are making progress in their attempts to develop a cure for the disease.

NanoViricides: One Step at a Time

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of NanoViricides, Inc. (“NanoViricides” or “the Company”) (NYSE: NNVC) for violations of the securities laws.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against NanoViricides, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

Gilead Sciences

As the world struggles to return to normalcy in the wake of the Covid-19 pandemic, pharma companies are in the process of building various potential therapies to counter the virus.

NanoViricides to Use Gilead Sciences' Remdesivir in Potential Covid Therapy

PHILADELPHIA, Sept. 8, 2020 /PRNewswire/ -- Kehoe Law Firm, P.C.

NanoViricides, Inc. Investors Who Purchased NNVC Securities Between January 23, 2020 and July 13, 2020 And Suffered Significant Losses Encouraged To Contact Kehoe Law Firm, P.C.

NanoViricides, Inc. (AMEX:NNVC) has consistently been in the news over the past few months owing to its efforts to develop a novel drug to counter the novel coronavirus, SARS-CoV-2.

NanoViricides: Ready for the IND Application for a Novel Covid-19 Drug

New York, New York--(Newsfile Corp. - August 31, 2020) -  NanoViricides, Inc.

Small Caps Daily Features NanoViricides' Progress on Developing a Therapy To Help Kids Return To School Safely

The Company's successful fundraising and inclusion in the Russell Microcap(R) Index comes after a series of promising test results for its COVID-19 drug candidatesShelton, Connecticut--(Newsfile Corp. - July 23, 2020) - NanoViricides, Inc.

NanoViricides, Inc. Raises $11.5 Million Through Public Offering After Positive Test Results For COVID-19 Drug

LOS ANGELES--(BUSINESS WIRE)---- $NNVC #fraud--Glancy Prongay & Murray LLP, a National Class Action Law Firm, Announces Investigation of NanoViricides, Inc. (NNVC) on Behalf of Investors

Glancy Prongay & Murray LLP, a National Class Action Law Firm, Announces Investigation of NanoViricides, Inc. (NNVC) on Behalf of Investors

SAN FRANCISCO, July 15, 2020 /PRNewswire/ -- Hagens Berman urges investors in NanoViricides, Inc. (NNVC) to submit their losses now.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Notifies NanoViricides (NNVC) Investors of Proprietary Investigation into Possible Securities Law Violations, Encourages Investors and Persons Who May be Able to Assist Investigation to Contact Firm

As the coronavirus was spreading in China, a small biopharma company, NanoViricides, claimed it was close to clinical trials for a treatment. A CNBC investigation found the 15-year-old company has never tested a product in humans or made any revenue.

Cashing in on coronavirus: Small biopharma company NanoViricides sees stock soar on treatment claims

NanoViricides Inc. (NYSE: NNVC) made another stride in the fight against COVID-19, and investors have to be happy about it.

NanoViricides COVID-19 Treatment Offers Alternative to Antibodies

NanoViricides (NYSE: NNVC) shares are trading higher after the company announced the drug candidates it's developing against the coronavirus demonstrated safety and tolerability in an animal model.

Why NanoViricides Stock Is Trading Higher Today

Thermo Fisher Scientific

Taiwan Semiconductor Manufacturing

The global nanotechnology market could exceed $125 billion by 2024, as it continues to impact technology, energy, defense, and even food.

3 Nanotech Stocks for Big Growth

Biotech and pharma companies all over the world are engaged in the development and testing process of their respective drug and vaccine candidates to counter the Covid-19 pandemic.

NanoViricides: New Covid-19 Drug Candidates Could Boost Performance

NanoViricides Inc. (NNVC) has been one of the most widely covered micro caps within the antiviral space ever since the outbreak of the novel coronavirus (Covid-19).

NanoViricides: The Visit From Senator Blumenthal Is a Positive Development

Anil Diwan typically runs on six hours of sleep, but he’s no stranger to two-week stretches of three hours or less.

NanoViricides Searches For Coronavirus Treatment In Ligand Library: 'A Humanitarian Thing To Do'

Altimmune

Aytu BioScience

Clorox

Co-Diagnostics

Quest Diagnostics

Inovio Pharmaceuticals

Lakeland Industries

Novavax

Zoom Video

Markets looked like they would be crushed yet again on Monday despite the emergency Federal Reserve rate cut announced on Sunday.

How Coronavirus Stocks Were Holding Up in Monday’s Sell-Off

Markets were crushed again on Thursday after President Trump announced a travel ban to Europe on Wednesday night.

How Coronavirus Stocks Responded to Thursday’s Sell-Off

Moderna

Regeneron Pharmaceuticals

COVID-19 has rocked markets and caused panic across the world. While investors are feeling the pain as global supply chains may become constricted, playing on COVID-19 stocks has proven very lucrative.

Coronavirus Stocks See Rising Tide in Short Interest

Cocrystal Pharma

GlaxoSmithKline

Johnson & Johnson

Pfizer

Sanofi

Vaxart

The COVID-19 virus has sent the market and the global economy into a tailspin. The Organisation for Economic Co-operation and Development slashed its global growth forecast for 2020 Monday by 0.5 points to 2.5% versus already-weak 2.9% growth in 2019.

How Close Are Biotechs To Bringing A COVID-19 Treatment To Market?

Enzo Biochem

OPKO Health

Spherix

The COVID-19 outbreak has proved to be a catalyst for biotechs. Some issues that were wallowing in penny stock territory have posted stratospheric gains in the wake of efforts to develop diagnostic tests, treatments and vaccines to combat the new coronavirus.

4 Biotech Stocks Moving On COVID-19 Updates

The coronavirus fear is now a pandemic, at least in the markets. All major American averages were down over 3% on Friday, after what has been the worst week since the financial crisis more than a decade ago.

The Top Stocks to Beat the Coronavirus Market Scare

News for NanoViricides Stock (NNVC)